A previously published paper also compared the cost-effectiveness of cemiplimab versus platinum-based chemotherapy, yielding an ICERs of $40,390/QALY in patients with advanced NSCLC with high PD-L1 expression (46). The gene discussed is CD274; the disease is non-small cell lung carcinoma.